FAI
NVO

Fiduciary Advisors Inc’s Novo Nordisk NVO Stock Holding History

Fiduciary Advisors Inc’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-8
Closed -$444 – 128
2025
Q3 		$444 Hold
8
– – ﹤0.01% 95
2025
Q2 		$553 Hold
8
– – ﹤0.01% 94
2025
Q1 		$556 Hold
8
– – ﹤0.01% 94
2024
Q4 		$689 Buy
+8
New +$865 ﹤0.01% 98

Other funds holding NVO

Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fiduciary Advisors Inc's NVO Position: Q4 2025 in Review

Fiduciary Advisors Inc sold out of Novo Nordisk (NVO) in Q4 2025, closing a stake of 8 shares — an estimated $444 sold.

Fiduciary Advisors Inc first reported a position in NVO in Q4 2024 and held it in 4 quarters. The position peaked at $689 in Q4 2024. 1,413 funds tracked by Wall St. Rank hold NVO as of Q4 2025.

  • Fiduciary Advisors Inc reported no remaining Novo Nordisk position as of Q4 2025 after selling out during the quarter.
  • Fiduciary Advisors Inc sold 8 Novo Nordisk shares in Q4 2025, an estimated $444.
  • Fiduciary Advisors Inc first reported a position in Novo Nordisk in Q4 2024 and held it in 4 quarters.
  • Fiduciary Advisors Inc's Novo Nordisk position peaked at $689 in Q4 2024.
  • 1,413 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2025.

Based on Fiduciary Advisors Inc's 13F filing for Q4 2025, filed 27 Jan 2026.